Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders

Publication date: Available online 21 December 2018

Source: The Journal of Allergy and Clinical Immunology: In Practice

Author(s): Katherine M. Harris, Blachy J. Davila, Catherine M. Bollard, Michael D. Keller

Viral infections are common and can be potentially fatal in patients with primary immunodeficiency disorders (PIDDs). Because viral susceptibility stems from poor to absent T-cell function in most patients with moderate to severe forms of PIDD, adoptive immunotherapy with virus-specific T cells (VSTs) has been used to combat viral infections in the setting of hematopoietic stem cell transplantation in multiple clinical trials. Most trials to date have targeted cytomegalovirus, EBV, and adenovirus either alone or in combination, although newer trials have expanded the number of targeted pathogens. Use of banked VSTs produced from third-party donors has also been studied as a method of expanding access to this therapy. Here we review the clinical experience with VST therapy for patients with PIDDs as well as future potential targets and approaches for the use of VSTs to improve clinical outcomes for this specific patient population.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2BC2PzZ